Study type: Human research · Status: Evidence verified by machine against declared source
Cerebrolysin for the Treatment of Aneurysmal Subarachnoid Hemorrhage in Adults: A Retrospective Chart Review
Advances in therapy · 2018
Study scale: Subgroup analyses were performed according to Hunt and Hess grade (good grade ≤ 2, N = 216; poor grade ≥ 3, N = 246) and treatment procedure (clip or coil).
Abstract only: Open source record
Product or molecular entity relationships
- Cerebrolysin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.
Public plain-language summary
Some fields are not published, because the text held for them did not answer their heading. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
To our knowledge, this drug has never been evaluated in patients with aneurysmal subarachnoid hemorrhage (SAH).
Study design
Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.
Participants or experimental system
The aim of this study was to evaluate the effect of Cerebrolysin in patients with aneurysmal SAH.
Study scale
Subgroup analyses were performed according to Hunt and Hess grade (good grade ≤ 2, N = 216; poor grade ≥ 3, N = 246) and treatment procedure (clip or coil).
Intervention or exposure
Cerebrolysin is a neuroprotective drug used in the treatment of acute ischemic stroke.
Comparator
Patients received Cerebrolysin treatment or standard care only (control group).
Outcomes examined
However, treatment remains insufficient, and drugs to improve patient outcomes are not well established.
Key findings
In good-grade patients (N = 216), clinical outcomes and mortality did not differ significantly between the control and Cerebrolysin groups.
Limitations and uncertainty
Further studies are needed to confirm our results.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.